Table 1.
Baseline characteristics of the overall cohort
| Low-risk | Intermediate-risk | High-risk | |
|---|---|---|---|
| Mean age, years (95% CI) | 58.62 (57.78, 59.46) | 61.18 (60.65, 61.72) | 63.71 (62.49, 64.93) |
| Mean PSA, ng/ml (95% CI) | 5.09 (4.85, 5.33) | 6.47 (6.20, 6.74) | 11.14 (9.14, 13.13) |
| Mean biopsy Gleason score | 6 | 6.93 | 7.93 |
| Gleason score, n (%) | 240 (100) | ||
| 6 | 30 (6.07) | 4 (4.04) | |
| 3 + 4 | 364 (73.68) | 10 (10.10) | |
| 4 + 3 | 100 (20.24) | 7 (7.07) | |
| 8–10 | 78 (78.78) | ||
| Clinical stage, n (%) | |||
| cT1b | 1 (1.01) | ||
| cT1c | 205 (85.41) | 356 (72.06) | 45 (45.45) |
| cT2a | 35 (14.58) | 110 (22.26) | 24 (24.24) |
| cT2b | 28 (5.66) | 14 (14.14) | |
| cT2c | 10 (10.10) | ||
| cT3 | 5 (5.05) | ||
| Mean TRUS prostate volume (95% CI) | 31.58 (30.99, 32.18) | 31.60 (31.11, 32.08) | 31.74 (30.69, 32.78) |
| Mean BMI (95% CI) | 38.93 (36.91, 40.96) | 39.83 (38.32, 41.34) | 41.45 (37.74, 45.16) |
BMI: body mass index; CI: confidence interval; PSA: prostate-specific antigen; TRUS: transrectal ultrasound.